Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia.

× No keyword cloud information.

7 in total

1. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.

Authors: Nicolò Compagno; Francesco Cinetto; Gianpietro Semenzato; Carlo Agostini
Journal: Haematologica Date: 2014-03-28 Impact factor: 9.941

2. Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases.

Authors: Emilio Besada; Lucius Bader; Hans Nossent
Journal: Rheumatol Int Date: 2011-12-30 Impact factor: 2.631

3. Persistence of Virus-Specific Antibody after Depletion of Memory B Cells.

Authors: William A Langley; Andreas Wieland; Hasan Ahmed; Mohammed Ata Ur Rasheed; Carl W Davis; Jaturong Sewatanon; Scott N Mueller; Mark J Shlomchik; Veronika I Zarnitsyna; Rustom Antia; Rafi Ahmed
Journal: J Virol Date: 2022-04-11 Impact factor: 6.549

4. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

Authors: Lawrence G Lum; Archana Thakur; Qin Liu; Abhinav Deol; Zaid Al-Kadhimi; Lois Ayash; Muneer H Abidi; Cassara Pray; Elyse N Tomaszewski; Patricia A Steele; Dana L Schalk; Hiroshi Yano; Alice Mitchell; Melissa Dufresne; Joseph P Uberti; Voravit Ratanatharathorn
Journal: Biol Blood Marrow Transplant Date: 2013-03-22 Impact factor: 5.742

Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia.

1. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.

2. Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases.

3. Persistence of Virus-Specific Antibody after Depletion of Memory B Cells.

4. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

5. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome.

Review 6. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.

7. Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab.